IKT Stock Analysis: Buy, Sell, or Hold?
IKT - Inhibikase Therapeutics, Inc. Common Stock
$1.63
-0.10 (-5.78%)
▼
5d:
-19.7%
30d:
-10.93%
90d:
-3.55%
WAIT
LOW Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 13, 2026
0d
Get Alerted When IKT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: IKT is down 19.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: IKT is down 19.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: IKT is currently trading at $1.63, which is considered slightly high relative to its 30-day fair value range of $1.74 to $1.96.
Technical Outlook: Technically, IKT is showing support break momentum. The price is currently testing key support at $1.64. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.8% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.00 (+246.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, IKT is showing support break momentum. The price is currently testing key support at $1.64. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.8% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.00 (+246.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$1.74 -
$1.96
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.6%
All Signals
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.8%)
- BULLISH: Trading 246.8% below Wall St target ($6.00)
- WARNING: Recommendation downgraded due to -19.7% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$1.74 -
$1.96
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$1.64
Resistance Level
$2.13
Current Trend
Support Break
Technical data as of
May 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.55
Wall Street Target
$6.00
(+246.8%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: May 18, 2026 1:42 PM ET
Data refreshes hourly during market hours. Next update: 2:42 PM
Data refreshes hourly during market hours. Next update: 2:42 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IKT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 65 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$55 | 57 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$875 | 53 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 56 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 55 HOLD |
